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A B S T R A C T
Purpose
To update the recommendations for the use of bisphosphonates in the prevention and treatment
of bone disease in multiple myeloma. The Update Committee expanded the guideline to include
a discussion of osteonecrosis of the jaw (ONJ).
Methods
For the 2007 update, an Update Committee composed of members from the full panel completed
a review and analysis of data published since 2002. Searches of Medline and the Cochrane
Collaboration Library databases were performed.
Recommendations
For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic
destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90
mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every
3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide,
except in the United States, for oral or intravenous administration. New dosing guidelines for
patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although
no similar dosing guidelines are available for pamidronate, the Update Committee recommends that
clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment.
Zoledronic acid has not been studied in patients with severe renal impairment and is not recom-
mended in this setting. The Update Committee suggests that bisphosphonate treatment continue for
a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in
patients with responsive or stable disease, but further use is at the discretion of the treating physician.
The Update Committee also discusses measures regarding ONJ.
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INTRODUCTION
The American Society of Clinical Oncology (ASCO)
first published evidence-based clinical practice guide-
lines on the role of bisphosphonates in multiple my-
eloma in 2002. ASCO guidelines are updated at
intervals by an Update Committee of the original Ex-
pert Panel. The Update Committee has expanded the
scope of the guidelines to include recommendations
concerning the association of osteonecrosis of the jaw
(ONJ) and bisphosphonate therapy (Table 1 provides
a summary of the guideline recommendations).
UPDATE METHODOLOGY
For the 2007 update, an Update Committee com-
posed of members from the full Expert Panel (Ap-
pendix 1) was formed to complete the review and
analysis of data published since 2002. The Update
Committee’s literature review focused attention on
available randomized clinical trials, clinical practice
guidelines, and systematic reviews of published clin-
ical trials and a meta-analysis report. For the guide-
line recommendations related to ONJ, the Update
Committee considered data and reports from man-
ufacturers of bisphosphonates, governmental agen-
cies, and other dental and medical professional
societies. Details of the literature searches are pro-
vided in Appendix 2.
The Update Committee held a single face-to-
face meeting to consider the evidence for each of the
2007 recommendations. Additional work to com-
plete the update was completed via teleconferences
with the steering group and with the full Update
Committee. Representatives from industry attended
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Table 1. Summary of Recommendations
Specific Recommendations 2007 Recommendations
Lytic disease on plain radiographs or imaging studies For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic
destruction of bone or compression fracture of the spine from osteopenia, intravenous
pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at
least 15 minutes every 3 to 4 weeks is recommended. In light of data from Zervas et al1
showing a 9.5-fold greater risk for the development of osteonecrosis of the jaw with
zoledronic acid compared with pamidronate, patients may prefer pamidronate to zoledronic
acid until more data become available on this adverse effect of bisphosphonate therapy.
Clodronate is an alternative bisphosphonate approved worldwide, except in the United States,
for either oral or intravenous administration.
Monitoring As a result of increased concerns over renal adverse events, new dosing guidelines for patients
with pre-existing renal impairment were added to the zoledronic acid package insert. The new
guidelines recommend that patients with pre-existing mild-to-moderate renal impairment
(estimated creatinine clearance, 30 to 60 mL/min) should receive a reduced dosage of
zoledronic acid. No changes in infusion time or interval are required. Zoledronic acid has not
been studied in patients with severe renal impairment and is not recommended for use in
these patients. Pamidronate 90 mg administered over 4 to 6 hours is recommended for
patients with extensive bone disease and existing severe renal impairment (serum creatinine
level  3.0 mg/dL 265 mol/L or an estimated creatinine clearance  30 mL/min). Although
no dosing guidelines are available for patients with pre-existing renal impairment, the Update
Committee recommends that clinicians consider reducing the initial pamidronate dose in that
setting. Infusion times less than 2 hours with pamidronate or less than 15 minutes with
zoledronic acid should be avoided. The Update Committee recommends that serum creatinine
should be monitored before each dose of pamidronate or zoledronic acid, in accordance with
FDA-approved labeling. In patients who develop renal deterioration without apparent cause
during bisphosphonate therapy, zoledronic acid or pamidronate should be withheld.
Bisphosphonate therapy can be resumed, at the same dosage as that before treatment
interruption, when the serum creatinine returns to within 10% of the baseline level. Serum
calcium, electrolytes, phosphate, magnesium, and hematocrit/hemoglobin should also be
monitored regularly, although there is no evidence on which to base a recommendation for
time intervals. The Update Committee also recommends intermittent evaluation (every 3 to 6
months) of all patients receiving pamidronate or zoledronic acid therapy for the presence of
albuminuria. In patients experiencing unexplained albuminuria (defined as  500 mg/24 hours
of urinary albumin), discontinuation of the drug is advised until the renal problems are
resolved. These patients should be reassessed every 3 to 4 weeks (with a 24-hour urine
collection for total protein and urine protein electrophoresis), and pamidronate should be
reinstituted over a longer infusion time ( 4 hours) and at doses not to exceed 90 mg every 4
weeks when the renal function returns to baseline. The Update Committee supports the use
of screening urinalysis for proteinuria but underscores that a 24-hour urine collection for
determination of total protein and electrophoresis is required if the test is positive. Although
no similar guidelines are available for zoledronic acid, some Update Committee members
recommend that zoledronic acid be reinstituted over a longer infusion time ( 30 minutes).
Duration of therapy A single randomized clinical trial has shown no benefit of monthly bisphosphonates after a
tandem transplantation.2 There was no difference in the proportion of skeletal events in the
pamidronate-containing regimens (21% and 18%) compared with no maintenance (24%) after
29 months of follow-up. The Update Committee suggests that therapy with bisphosphonates
be administered monthly for a period 2 years. (The trial by Attal et al2 suggests 1 year if the
patient is in a CR or NCR after a tandem transplantation.) At 2 years, the physician should
seriously consider stopping bisphosphonates in patients with responsive or stable disease,
but their further use is at the discretion of the treating physician. There are no data to support
a more precise recommendation for duration of bisphosphonate therapy in this group of
patients. For those patients in whom bisphosphonates were withdrawn after 2 years, the
drug should be resumed upon relapse with new-onset skeletal-related events.
Myeloma patients with osteopenia based on normal
plain radiograph or bone mineral density
measurements
There is no change from the original guideline recommendation. It is reasonable to start
intravenous bisphosphonates in multiple myeloma patients with osteopenia but no
radiographic evidence of lytic bone disease. Note, patients with nonlytic lesions have been
included in selected trials but have not been the primary focus of the trial or of sufficient
number to be separately analyzed.
Patients with solitary plasmacytoma or smoldering or
indolent myeloma without documented lytic
bone disease
There is no change from the original guideline recommendation. Starting bisphosphonates in
patients with solitary plasmacytoma or smoldering (asymptomatic) or indolent myeloma is not
recommended.
Patients with monoclonal gammopathy of
undetermined significance
There is no change from the original guideline recommendation. Starting bisphosphonates in
patients with monoclonal gammopathy of undetermined significance is not recommended.
Biochemical markers There is no change from the original guideline recommendation The use of the biochemical
markers of bone metabolism to monitor bisphosphonate use is not suggested for routine care
Role in pain control secondary to bony involvement There is no change from the original guideline recommendation. Intravenous pamidronate or
zoledronic acid is recommended for patients with pain as a result of osteolytic disease and as
an adjunctive treatment for patients receiving radiation therapy, analgesics, or surgical
intervention to stabilize fractures or impending fractures.
Osteonecrosis of the jaw* Osteonecrosis of the jaw is an uncommon but potentially serious complication of intravenous
bisphosphonates. The Update Committee agrees with the recommendations described in the
revised FDA label for zoledronic acid and pamidronate, Dear Doctor letters, a white paper, and
various position papers or statements. All cancer patients should receive a comprehensive
dental examination and appropriate preventive dentistry before bisphosphonate therapy.
Active oral infections should be treated, and sites at high risk for infection should be
eliminated. While on therapy, patients should maintain excellent oral hygiene and avoid
invasive dental procedures, if possible.
Abbreviations: FDA, Food and Drug Administration; CR, complete response; NCR, near complete response.
*This topic is new to the guideline.
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the Update Committee meeting and provided preprints and reprints
of relevant studies. The guideline was circulated in draft form to the
Update Committee. ASCO’s Health Services Committee and the
ASCO Board of Directors also reviewed the final document.
It important to emphasize that guidelines and technology assess-
ments cannot always account for individual variation among patients.
They are not intended to supplant physician judgment with respect to
particular patients or special clinical situations and cannot be consid-
ered inclusive of all proper methods of care or exclusive of other
treatments reasonably directed at obtaining the same result.
Accordingly, ASCO considers adherence to this guideline as-
sessment to be voluntary, with the ultimate determination regard-
ing its application to be made by the physician in light of each
patient’s individual circumstances. In addition, this guideline de-
scribes the use of procedures and therapies in clinical practice; it
cannot be assumed to apply to the use of these interventions
performed in the context of clinical trials, given that clinical studies
are designed to evaluate or validate innovative approaches in a
disease for which improved staging and treatment is needed. Be-
cause guideline development involves a review and synthesis of the
latest literature, a practice guideline also serves to identify impor-
tant questions and settings for further research.
SUMMARY OF LITERATURE REVIEW RESULTS
The literature search conducted for this update identified several rel-
evant reports, including two articles reporting the results of random-
ized clinical trials, one clinical practice guideline, one consensus
statement,3 and two systematic reviews of the literature. One of the
randomized clinical trials identified evaluated the effect of pamidro-
nate on skeletal events and disease progression in patients with early-
stage, untreated multiple myeloma.4 A second report presented the
results of a 25-month final analysis of a previously published random-
ized clinical trial that compared the safety and efficacy of pamidronate
and zoledronic acid.5 The clinical practice guideline, which was devel-
oped by the Cancer Care Ontario Program in Evidence-Based Care,6
addressed the role of bisphosphonates in the management of skeletal
complications for patients with multiple myeloma.6 This guideline
was based in large part on the Cochrane Collaboration systematic
review and meta-analysis conducted by Djulbegovic et al.7 The con-
sensus statement was developed by a multidisciplinary panel at the
Mayo Clinic that included hematologists, dental specialists, and
nurses specializing in the treatment of multiple myeloma. The state-
ment addressed the choice of a bisphosphonate for multiple myeloma
patients, duration of therapy, and adverse events associated with
bisphosphonate therapy.3 Finally, the systematic reviews analyzed the
role of bisphosphonates in metastatic disease8 and the role of bisphos-
phonates in the relief of pain secondary to bone metastases.9 The
results of the two randomized clinical trials and the two systematic
reviews are summarized in the relevant literature update and discus-
sion sections that follow.
GUIDELINE RECOMMENDATIONS
Lytic Disease on Plain Radiographs or Imaging
2007 recommendation. For multiple myeloma patients who
have, on plain radiograph(s) or imaging, lytic destruction of bone or
compression fracture of the spine from osteopenia, intravenous pam-
idronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg
delivered over at least 15 minutes every 3 to 4 weeks is recommended.
In light of data from Zervas et al1 showing a 9.5-fold greater risk for the
development of ONJ with zoledronic acid compared with pamidro-
nate, patients may prefer pamidronate to zoledronic acid until more
data become available on this adverse effect of bisphosphonate ther-
apy. Clodronate is an alternative bisphosphonate that has been ap-
proved worldwide, except in the United States, for either oral or
intravenous administration.
Literature update and discussion. The literature search for the
2007 guideline identified an updated analysis of a previously published
randomized clinical trial. Rosen et al5 reported data from a large phase
III randomized trial that compared 4- or 8-mg doses of zoledronic acid
with 90 mg of pamidronate every 3 to 4 weeks in patients with multiple
myeloma or breast cancer who had lytic disease.10 After a follow-up
period of 25 months, zoledronic acid reduced the overall proportion
of patients with a skeletal-related event and reduced the skeletal mor-
bidity to an extent similar to that for pamidronate. Compared with
pamidronate, zoledronic acid reduced the overall risk of developing
skeletal complications (including hypercalcemia) by an additional
16% (P  .03).
A systematic review of the literature (1966 to 2001) by Ross et al8
on the use of bisphosphonates in metastatic disease, including multi-
ple myeloma, was published in 2004. There is considerable overlap
between this review and the Cochrane Collaboration systematic re-
view published by Djulbegovic et al7 in 2002 that was featured in the
original ASCO guideline for bisphosphonates in multiple myeloma.
Ross et al8 included nine of the 11 trials that were considered in the
Cochrane Collaboration systematic review.
Ross et al8 pooled data from three randomized clinical trials with
a total of 1,079 patients for vertebral fractures, combined fractures,
and hypercalcemia skeletal morbidity outcomes. The results indicated
that, compared with placebo, bisphosphonate therapy significantly
reduced the risk of vertebral fractures but not combined fractures
or hypercalcemia (Table 2). Combined analyses of the effect of
Table 2. Summary Statistics From Subgroup Analysis of Skeletal Morbidity End Points From Multiple Trials
Skeletal Morbidity Outcome Odds Ratio 95% CI No. of Studies No. of Patients P
Vertebral fractures: yes v no 0.583 0.419 to 0.812 2 913 .001
Combined fractures: yes v no 0.776 0.539 to 1.120 2 543 .175
Hypercalcemia: yes v no 0.968 0.687 to 1.365 3 1,079 .852
NOTE. Adapted with permission.8
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bisphosphonates on survival outcomes were not reported for the
multiple myeloma subset of the trials in the systematic review.
Monitoring
2007 recommendations. As a result of increased concerns over
renal adverse events, new dosing guidelines for patients with pre-
existing renal impairment were added to the zoledronic acid package
insert. The new guidelines recommend that patients with pre-existing
mild-to-moderate renal impairment (estimated creatinine clearance,
30 to 60 mL/min) should receive a reduced dosage of zoledronic acid.
No changes in infusion time or interval are required. Zoledronic acid
has not been studied in patients with severe renal impairment and is
not recommended for use in these patients. Pamidronate 90 mg ad-
ministered over 4 to 6 hours is recommended for patients with exten-
sive bone disease and existing severe renal impairment (serum
creatinine level  3.0 mg/dL [265 mol/L] or an estimated creatinine
clearance  30 mL/min). Although no dosing guidelines are available
for patients with pre–existing renal impairment, the Update Commit-
tee recommends that clinicians consider reducing the initial pamidro-
nate dose in that setting.
Infusion times less than 2 hours with pamidronate or less than 15
minutes with zoledronic acid should be avoided. The Update Com-
mittee recommends that serum creatinine should be monitored be-
fore each dose of pamidronate or zoledronic acid, in accordance with
US Food and Drug Administration–approved labeling. In patients
who develop renal deterioration with no other apparent cause during
bisphosphonate therapy, zoledronic acid or pamidronate should be
withheld. Bisphosphonate therapy can be resumed, at the same dosage
as that before treatment interruption, when the serum creatinine
returns to within 10% of the baseline level. Serum calcium, electro-
lytes, phosphate, magnesium, and hematocrit/hemoglobin should
also be monitored regularly, although there is no evidence on which to
base a recommendation for time intervals. The Update Committee
also recommends intermittent evaluation (every 3 to 6 months) of all
patients receiving pamidronate or zoledronic acid therapy for the
presence of albuminuria. In patients experiencing unexplained albu-
minuria (defined as  500 mg/24 hours of urinary albumin), discon-
tinuation of the drug is advised until the renal problems are resolved.
When the proteinuria returns to baseline, these patients should be
reassessed every 3 to 4 weeks (with a 24-hour urine collection for total
protein and urine protein electrophoresis), and pamidronate should
be reinstituted over a longer infusion time ( 4 hours) and at doses
not to exceed 90 mg every 4 weeks. The Update Committee supports
the use of screening urinalysis for proteinuria but underscores that a
24-hour urine collection for determination of total protein and elec-
trophoresis is required if the screening test is positive. Although no
similar guidelines are available for zoledronic acid, some Update
Committee members recommend that zoledronic acid be reinstituted
over a longer infusion time ( 30 minutes).
Literature update and discussion. Zoledronic acid and pamidro-
nate are associated with renal deterioration, particularly in patients
with pre-existing renal impairment and in patients who receive mul-
tiple cycles of therapy. In several randomized comparisons of
zoledronic acid (4 mg as a 15-minute infusion) versus pamidronate
(90 mg as a 2-hour infusion) or placebo, approximately 12% of pa-
tients with multiple myeloma, breast cancer, or other solid tumors
developed evidence of renal deterioration during the study period (up
to 24 months). In these studies, which involved more than 1,000
patients, deterioration of renal function was defined as a change in
baseline serum creatinine  0.5 mg/dL or  two times the baseline
value in patients with a normal baseline serum creatinine level ( 1.4
mg/dL) or a change from baseline serum creatinine  1.0 mg/dL or
 two times the baseline value in patients with an abnormal baseline
serum creatinine ( 1.4 mg/dL). In the randomized comparison of
zoledronic acid versus pamidronate, the incidence of renal deteriora-
tion was similar in the two groups.5 In the placebo-controlled trials,
the risk of renal deterioration was higher in patients who received
zoledronic acid compared with patients randomly assigned to the
placebo group (13.2% v 8.7%, respectively).5,11 In the subgroup of
patients with abnormal serum creatinine, the risk seemed to be higher
in the zoledronic acid group compared with the placebo group (23.8%
v 10%, respectively). In another analysis based on estimated creatinine
clearance, patients in the zoledronic acid group with pre-existing
moderate renal impairment (creatinine clearance of 30 to 49 mL/min)
showed the highest risk of renal deterioration compared with the
placebo group (32.1% v 7.7%, respectively).12 No difference was ob-
served in patients with pre-existing mild renal impairment (creatinine
clearance of 50 to 69 mL/min) who received zoledronic acid compared
with the placebo group (7.5% v 9.0%, respectively). Given these ob-
servations, new dosing guidelines for patients with pre-existing renal
impairment were added to the zoledronic acid package insert in Jan-
uary of 2005. These guidelines recommend a lower initial zoledronic
acid dose (ranging from 3.0 to 3.5 mg) depending on the estimated
creatinine clearance. The lower doses were calculated to achieve the
same area under the curve as that achieved in patients with a
creatinine clearance of 75 mL/min. Although no similar dosing
guidelines are available for pamidronate, the Update Committee
recommends that clinicians consider reducing the initial pami-
dronate dose in patients with pre-existing renal impairment.
Oral and intravenous ibandronate may have a different renal
safety profile than pamidronate and zoledronic acid. In randomized
placebo-controlled trials, the incidence of renal adverse effects with
oral and intravenous ibandronate was similar to that observed with
placebo (approximately 5% in both groups). However, no definitive
conclusions about the comparative safety of ibandronate versus
zoledronic acid can be reached. Randomized head-to-head compari-
sons of ibandronate versus zoledronic acid are planned or ongoing.
Data on the long-term renal safety of bisphosphonates are lim-
ited. In one series of 57 patients with cancer who were treated with
either pamidronate or pamidronate plus zoledronic acid every 3 to 4
weeks for more than 24 months (median, 34 months; range, 24 to
131 months), a notable increase in serum creatinine occurred in
seven patients (12%).13 Bisphosphonates were discontinued in one
patient and continued in the remaining six patients; in the six patients
who continued treatment, serum creatinine returned to normal in two
patients and did not increase in the other four patients. In another
series of 22 patients with cancer who were treated with intravenous
bisphosphonates for more than 24 months, four patients (22%) had a
notable increase in serum creatinine.14 The renal safety of alternative
dosing intervals (eg, every 12 weeks) of bisphosphonates is not known.
Renal deterioration can progress to renal failure and dialysis.15-20
Renal failure has occurred in patients with multiple myeloma, solid
tumors, and Paget’s disease. Most patients received pamidronate
alone, although some patients received pamidronate before
zoledronic acid. Renal biopsies, when performed, have shown various
glomerulopathies (eg, collapsing glomerulopathy, focal segmental
Kyle et al
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glomerulosclerosis) or toxic acute tubular necrosis. In one case series
of six patients with renal failure associated with zoledronic acid, it is
interesting to note that the renal biopsy results showed toxic acute
tubular necrosis without evidence of glomerular damage.18 However,
all of the six patients had been treated with pamidronate before
zoledronic acid. After drug discontinuation, renal function usually
improves but may not return to baseline levels.
It is essential that physicians infuse pamidronate 90 mg at a rate
no faster than 2 hours or zoledronic acid at a rate no faster than 15
minutes every 3 to 4 weeks. Physicians should not attempt to shorten
the infusion time, increase the dose, or reduce the dose interval.
The Update Committee recommends that serum creatinine
should be monitored before each dose of pamidronate or zoledronic
acid. Serum calcium, electrolytes, phosphate, magnesium, and hemat-
ocrit/hemoglobin should also be monitored regularly. The US Food
and Drug Administration–approved labeling provides no guidance
on time intervals for blood chemistry assessment, but it is specific on
pretreatment creatinine measurement. The Update Committee’s rec-
ommendation is consistent with the current US Food and Drug Ad-
ministration–approved guidelines in the pamidronate and zoledronic
acid package inserts. The Update Committee recognizes that it may be
difficult or inconvenient for some clinics to obtain results of renal
function tests before pamidronate or zoledronic acid administration.
However, the Update Committee recommends that the US Food and
Drug Administration–approved monitoring guidelines be followed.
Duration of Therapy
2007 recommendation. A single randomized clinical trial has
shown no benefit of monthly bisphosphonates after tandem stem-cell
transplantation.2 There was no difference in the proportion of skeletal
events in the pamidronate-containing regimens (21% and 18%) com-
pared with no maintenance (24%) after 29 months of follow-up.
Given these data and the best clinical opinion of the Update Commit-
tee, we suggest that therapy with bisphosphonates be administered
monthly for a period of 2 years. (The trial by Attal et al2 suggests 1 year
if the patient is in a complete response or near complete response after
a tandem stem-cell transplantation.) At 2 years, physicians should
seriously consider stopping bisphosphonates in patients with respon-
sive or stable disease, but their further use is at the discretion of the
treating physician. There are no data to support a more precise rec-
ommendation for duration of bisphosphonate therapy in this group
of patients. For those patients in whom bisphosphonates are with-
drawn after 2 years, the drug should be resumed on relapse with
new-onset skeletal-related events.
Literature update and discussion. Since the original guideline was
published, a single randomized clinical trial has been published that
relates to the question of the duration of bisphosphonate therapy in
patients with multiple myeloma. Attal et al2 conducted a randomized
clinical trial to evaluate the role of thalidomide and pamidronate as
maintenance therapy in multiple myeloma patients who had under-
gone tandem stem-cell transplantation. Two months after completing
high-dose therapy, 597 patients ( 65 years old) were randomly
assigned to one of the following three arms: no maintenance therapy,
pamidronate (intravenous infusion of 90 mg at 4-week intervals), or
pamidronate plus thalidomide. Groups were compared in terms of
response rates; 3-year risk of skeletal events; and event-free, relapse-
free, and overall survival. The proportions of patients with skeletal-
related events at 3 years were 24%, 21%, and 18% for patients
administered no maintenance therapy, pamidronate, and pamidro-
nate plus thalidomide, respectively (P  .40). Survival without skeletal
events did not differ among the three treatment groups (P  .20).
Myeloma Patients With Osteopenia Based on
Normal Plain Radiograph or Bone Mineral
Density Measurements
2007 recommendation. It is reasonable to start intravenous
bisphosphonates in multiple myeloma patients with osteopenia
but no radiographic evidence of lytic bone disease. Note, patients
with nonlytic lesions have been included in selected trials but have
not been the primary focus of the trial or of sufficient number to be
separately analyzed.
Literature update. There is no change from the original guide-
line recommendation. No relevant additional data on this topic were
identified from a review of the literature published since 2002.
Patients With Solitary Plasmacytoma or Smoldering
or Indolent Myeloma Without Documented Lytic
Bone Disease
2007 recommendation. Starting bisphosphonate therapy in pa-
tients with solitary plasmacytoma or smoldering (asymptomatic) or
indolent myeloma is not recommended.
Literature update and discussion. There is no change from the
original guideline recommendation. The literature search identified a
single relevant study. In this clinical trial,4 90 patients with untreated
stage I or II myeloma were randomly assigned to either receive or not
receive intravenous pamidronate for 1 year. After a median follow-up
time of 51 months, disease had progressed in 25% of patients ran-
domly assigned to pamidronate and in 26.8% of the controls. The
median time to progression was 16.0 months in patients who received
pamidronate and 17.4 months in controls. Of the 21 patients who
required therapy, skeletal events developed in 82% of controls and in
40% of the treated patients (P  .01). The authors concluded that the
administration of pamidronate may decrease the development of skel-
etal events. Pamidronate did not reduce the rate of or the time to
disease progression.4
Patients With Monoclonal Gammopathy of
Undetermined Significance
2007 recommendation. Starting bisphosphonate therapy in pa-
tients with monoclonal gammopathy of undetermined significance is
not recommended.
Literature update. There is no change from the original guide-
line recommendation. No relevant additional data on the use of
bisphosphonates for patients with monoclonal gammopathy of unde-
termined significance were identified from a review of the literature
published since 2002.
Biochemical Markers
2007 recommendation. The use of the biochemical markers of
bone metabolism to monitor bisphosphonate use is not suggested
for routine care because of a lack of prospective studies validating
such an approach.
Literature update and discussion. There is no change from the
original guideline recommendation. The literature search conducted
for the update identified two studies of note. A study of 441 patients
with prostate cancer, lung cancer, and other solid tumors reported
that elevated levels of N-telopeptide (NTX) were a stronger prognostic
Bisphosphonates in Multiple Myeloma Guidelines
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indicator of negative outcomes than bone-specific alkaline phospha-
tase levels. Patients with high NTX levels had an increased risk of
skeletal-related events and disease progression and shorter survival.21
In a second study,22 urinary measurements of NTX and serum bone
alkaline phosphatase were obtained in 1,824 bisphosphonate-treated
patients with breast cancer, prostate cancer, non–small-cell lung can-
cer, other solid tumors, or multiple myeloma. Patients with high and
moderate NTX levels had a two-fold increase in their risk of skeletal
complications and disease progression compared with patients with
low NTX levels (P  .001). Bone alkaline phosphatase showed some
correlation with a risk of negative clinical outcomes.22 Although the
results of these studies are interesting, at this time, the use of these
markers should only be practiced within research protocols and have
no role in routine care.
Role in Pain Control Secondary to Bony Involvement
2007 recommendation. Intravenous pamidronate or zoledronic
acid is recommended for patients with pain caused by osteolytic dis-
ease and as an adjunctive treatment for patients receiving radiation
therapy, analgesics, or surgical intervention to stabilize fractures or
impending fractures.
Literature update and discussion. There is no change from the
original guideline recommendation. The literature review identified a
Cochrane Collaboration systematic review on the topic of bisphos-
phonates for the relief of pain secondary to metastases that was con-
ducted since the original guideline was published in 2002. Wong and
Wiffen9 identified 30 randomized controlled studies (with a total of
3,682 patients) that investigated the effectiveness of bisphosphonates
for pain relief in patients with painful bony metastases from any
primary neoplasms (including breast cancer, multiple myeloma, pros-
tate cancer, and any primary cancer site). There were few studies with
available data for any of the outcomes considered. Wong and Wiffen9
grouped studies by primary disease site using the outcome of the
proportion of patients with pain relief within 12 weeks of bisphospho-
nate therapy. Using this outcome criterion, just one trial of multiple
myeloma patients was identified.23 The authors concluded that the
small number of studies across primary diseases sites did not permit
conclusions concerning the relative effectiveness of bisphosphonates.
The Expert Panel recommendation from the original (2002) guide-
line, based on the trial by Berenson et al23 and panel consensus,
remains in effect.
Safety and Adverse Effects: ONJ
NOTE. The topic of ONJ as an adverse effect is new to the guideline.
2007 recommendation. ONJ is an uncommon but potentially
serious complication of intravenous bisphosphonates. The Update
Committee agrees with the recommendations described in the revised
US Food and Drug Administration label for zoledronic acid and
pamidronate, Dear Doctor letters, a white paper, and various position
papers or statements. All cancer patients should receive a comprehen-
sive dental examination and appropriate preventive dentistry before
bisphosphonate therapy. Active oral infections should be treated, and
sites at high risk for infection should be eliminated. While on therapy,
patients should maintain excellent oral hygiene and avoid invasive
dental procedures, if possible.
Review of the literature and discussion. ONJ is an uncommon but
potentially serious complication of intravenous bisphosphonate ther-
apy in cancer patients.24-28 The first spontaneous reports of ONJ in
cancer patients treated with bisphosphonates were received by the US
Food and Drug Administration in 2002, and the first published re-
ports of ONJ appeared in the literature in 2003. More than 300 cases of
ONJ associated with intravenous bisphosphonate use in patients with
cancer have been reported in the medical and dental literature.29
Novartis (East Hanover, NJ) has received 2,400 adverse event reports
of ONJ and/or osteomyelitis of the jaw.30 In response to growing
concerns over ONJ, the manufacturer revised the zoledronic acid and
pamidronate package inserts in late 2003 and again in 2004. In addi-
tion, Novartis issued Dear Doctor letters concerning ONJ to physi-
cians in September 2004 and to dentists in May 2005 and supported
the development of a white paper on ONJ based on an expert multi-
disciplinary panel, which was distributed to health care professionals
in June 2004 and later published.31
On the basis of several observational studies, the risk of ONJ in
cancer patients treated with intravenous bisphosphonates ranges from
1% to 11%, depending on the specific bisphosphonate, bisphospho-
nate dose, duration of treatment, and dental history.1,32-36 However,
these figures should be considered estimates because the baseline risk
of ONJ in cancer patients not receiving intravenous bisphosphonates
is not known. In a retrospective study of 4,000 cancer patients treated
with intravenous bisphosphonate therapy at M.D. Anderson Cancer
Center, 33 patients (0.83%) with ONJ were identified.35 The low
incidence reported in that series may be related to the inclusion of
many patients who received only a few courses of bisphosphonates
(median total dose of pamidronate and zoledronic acid was approxi-
mately 180 and 12 mg, respectively). The International Myeloma
Foundation conducted a Web-based survey of 1,203 patients to assess
the risk factors for ONJ.34 Sixty-two patients (6.8%) with myeloma
had ONJ, and an additional 54 had suspicious findings; 13 patients
(4.3%) with breast cancer had ONJ, and 23 had suspicious findings.
The most reliable estimates of the incidence of bisphosphonate-
associated ONJ are based on four cohort studies of cancer patients
receiving intravenous bisphosphonates (Table 3).1,32,33,36 Each study
had an adequate sample size and duration of exposure. The reported
incidence of bisphosphonate-associated ONJ ranged from 3.5% to
11% in those studies.
The role of bisphosphonates in the etiology of ONJ is not clear
because of the presence of other risk factors for ONJ, including previ-
ous or concomitant use of chemotherapy, radiotherapy, and cortico-
steroids. Although ONJ can occur spontaneously, most cases occur
in patients after a tooth extraction or other invasive dental
procedure.24,29,32-34 The type and duration of exposure to (or total
dose of) bisphosphonate also seem to be important risk factors.
Zoledronic acid has been associated with a higher risk of ONJ than
pamidronate (or pamidronate followed by zoledronic acid) in several
observational studies (Table 3).1,32-35 With follow-up at 36 months,
the cumulative incidence of ONJ was 10% in patients receiving
zoledronic acid only compared with 4% in patients receiving pami-
dronate with or without zoledronic acid (P  .002).34 Zoledronic acid
was also associated with a higher cumulative hazard of ONJ (com-
pared with pamidronate) in two prospective cohort studies. In an-
other prospective cohort study, the relative risk of ONJ associated with
zoledronic acid was 9.5 compared with pamidronate alone (P  .042)
and 4.5 compared with pamidronate plus zoledronic acid (P  .018).1
The risk of ONJ seems to increase with time of exposure.24,32-36 In
prospective cohort studies, the cumulative hazard of ONJ increased
from 1% after 12 months of treatment to up to 11% at 4 years in one
Kyle et al
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study32 and from 1% at 12 months to 6% at 36 months and to 13% at
48 months in another study.33
Several groups and organizations have developed or issued recom-
mendations, position papers, or statements regarding bisphosphonate-
associated ONJ. In 2004, Novartis assembled an expert multidisciplinary
panel to review the literature and clinical evidence, identify risk factors
for ONJ, and develop clinical guidelines for the prevention, early
diagnosis, management, and multidisciplinary treatment of ONJ. The
panel’s recommendations were distributed as a white paper at the
2004 Annual ASCO Meeting and later published.31 More recently, the
American Academy of Oral Medicine and the American Academy of
Oral and Maxillofacial Pathology have published position papers,27,29
and the American Association of Endodontists has issued a position
statement.37 All of these documents agree that prevention of
bisphosphonate-associated ONJ is the best approach to the manage-
ment of this complication. The Update Committee agrees with the
recommendations described in the revised US Food and Drug Ad-
ministration label for zoledronic acid and pamidronate, Dear Doctor
letters, white paper, and various position papers or statements. All
cancer patients should receive a comprehensive dental examination
and appropriate preventive dentistry before bisphosphonate therapy.
Active oral infections should be treated, and sites at high risk for
infection should be eliminated. While on therapy, patients should
maintain excellent oral hygiene and avoid invasive dental procedures,
if possible.
Other Nonrenal Adverse Effects
The safety and frequency of other nonrenal adverse events
with zoledronic acid seem to be similar to pamidronate. The ad-
verse events were well characterized in the pamidronate versus
placebo trial,38 zoledronic acid versus placebo trials,5,11 and the
pamidronate versus zoledronic acid trials.10,39 The incidence of
most adverse effects in patients treated with pamidronate was
similar to that observed in the placebo group. Transient myalgias,
arthralgias, and flu-like symptoms with fever tend to occur more
often in patients treated with pamidronate or zoledronic acid than
placebo.5,11,38,40 These symptoms usually occur only after the first
and/or second infusion of pamidronate and are not an indication
to discontinue drug treatment. Ocular adverse effects from pam-
idronate are relatively rare but well-recognized complications that
were first reported in 1994.41 An updated review of case reports
found 17 patients with unilateral scleritis and one patient with
bilateral scleritis, usually within 6 hours to 2 days after intravenous
pamidronate. Six patients had positive rechallenge testing, with the
scleritis occurring again after a repeat drug exposure.42 Ocular
adverse effects have been reported with zoledronic acid43 and other
bisphosphonates.44
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Table 3. Incidence of Bisphosphonate-Associated ONJ




Incidence of ONJ (%)
Effect of Bisphosphonate or Duration
of TherapyMedian Range
Bamias et al32 Prospective cohort 252 patients: 111 MM,
70 BC, 46 PC
20 4-86 Overall: 6.7; MM: 9.9,
BC: 2.9, PC: 6.5
All patients with ONJ received ZA; cumulative
hazard of ONJ was higher with ZA
(P  .001); cumulative hazard of ONJ
increased from  1% after 12 months to
11% at 4 years
Dimopoulos et al33 Prospective cohort 202 patients with MM 29 4-123 7.4 14 of 15 patients with ONJ received ZA;
cumulative hazard of ONJ was higher with
ZA (P  .001); cumulative hazard of ONJ
increased from  1% after 12 months to
13% at 4 years
Zervas et al1 Prospective cohort 303 patients with MM;
49 did not receive
ZA or P
24 4-120 11 v 0 in patients who
did not receive ZA
or P
28 of 29 patients with ONJ received ZA;
relative risk of ONJ with ZA was 9.5 v
P alone and 4.5 v P  ZA (P  .05)
Tosi et al36 Retrospective cohort 259 patients with MM 10 4-35 3.5 All patients received ZA; risk of ONJ was
6.6% after 24 months
Abbreviations: ONJ, osteonecrosis of the jaw; MM, multiple myeloma; BC, breast cancer; PC, prostate cancer; ZA, zoledronic acid; P, pamidronate; BP, bisphosphonate.
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Appendix 1
2007 American Society of Clinical Oncology Bisphosphonates in Multiple Myeloma Guideline Update Panel
Kenneth Anderson, MD, Co-Chair, Dana-Farber Cancer Institute; Robert A. Kyle, MD, Co-Chair, Mayo Clinic; Patrick J. Flynn, MD,
Minnesota Oncology Hematology P.A.; Sundar Jagannath, MD, St Vincent’s Comprehensive Cancer Center; Susan Halabi, PhD, Duke
University Medical Center; Robert Orlowski, MD, PhD, University of North Carolina at Chapel Hill; David Roodman, MD, VA Pittsburgh
Healthcare System; Patricia Twilde, Patient Representative; and Gary C. Yee, Pharm D, University of Nebraska Medical Center.
Appendix 2
For the 2007 update, a methodology similar to that applied in the original American Society of Clinical Oncology (ASCO) practice guideline
for use of bisphosphonates in multiple myeloma was used. Pertinent information published from 2002 to 2007 was reviewed to address each of
the original guideline questions and the new topic of osteonecrosis of the jaw. The Medline database (National Library of Medicine, Bethesda,
MD) was searched to identify relevant information from published randomized clinical trials, systematic reviews, meta-analyses, and practice
guidelines for this update. A series of searches was conducted using the medical subject headings or text words “multiple myeloma” and
“bisphosphonates” and variants thereof. Targeted searches using broad inclusion criteria were conducted to identify relevant articles related to
osteonecrosis of the jaw. Search results were limited to human studies and English-language articles; editorials, letters, and commentaries were
excluded from consideration. The Cochrane Library was searched for available systematic reviews and meta-analyses with words “biphospho-
nates,” “bisphosphonates,” and “diphosphonates.” Directed searches based on the bibliographies of primary articles were also performed. Finally,
Update Committee members and ASCO staff contributed articles from their personal collections. Update Committee members reviewed the
resulting abstracts and titles that corresponded to their assigned section.
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